Evidence map›Paper›PMID 38791420›Full record

ArticleInternational journal of molecular sciences2024

Heterozygous

Styliani Sarrou, Ioanna Voulgaridi, Athanasia Fousika, Katerina Dadouli, Olympia Margaritopoulou, Ioannis Kakkas, Christos Hadjichristodoulou, Fani Kalala, Matthaios Speletas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Styliani SarrouDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0001-8134-9228
Ioanna VoulgaridiLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.ORCID 0000-0002-7352-0934
Athanasia FousikaDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Katerina DadouliLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.ORCID 0000-0002-8821-0795
Olympia MargaritopoulouDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Ioannis KakkasDepartment of Immunology and Histocompatibility, "Evaggelismos" General Hospital, 10676 Athens, Greece.
Christos HadjichristodoulouLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 41222 Larissa, Greece.ORCID 0000-0002-4769-8376
Fani KalalaDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Matthaios SpeletasDepartment of Immunology & Histocompatibility, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0003-1287-7734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with predominantly antibody deficiencies (PADs) display hypogammaglobulinemia with a high prevalence of infections, along with autoimmune manifestations, benign and malignant lymphoproliferation and granulomatous disease. It is noteworthy that PAD patients, even those with defects in the same causative genes, display a variable clinical phenotype, suggesting that additional genetic polymorphisms, located in either immune-related or non-immune-related genes, may affect their clinical and laboratory phenotype. In this context, we analyzed 80 PAD patients, including 70 with common variable immunodeficiency (CVID) for

Indexed as

alpha 1-AntitrypsinCommon Variable ImmunodeficiencyHeterozygoteAdolescentAdultAgammaglobulinemiaAgedAllelesChildFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPhenotypeYoung Adultalpha 1-AntitrypsinSERPINA1 protein, humanalpha-1 antitrypsincommon variable immunodeficiencyliver diseasepredominantly antibody deficienciesSERPINA1

Identifiers

PMID38791420
PMCPMC11120870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.